Stock listing

LSE:SCLP Scancell Holdings PLC Share Price

Home listing (LSE) of Scancell Holdings PLC

Follow Scancell Holdings PLC into a list and get an email when it puts out news.

Share price · LSE:SCLP

79.00p GBX (pence) 0.00 (0.0%)

Close on Nov 20, 2026

Past year -16.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
78.00p – 82.00p GBX (pence)Nov 20, 2026
Volume
113,783 sharesNov 20, 2026
Market cap
£107.2M GBPAt the close on Nov 20, 2026 · price × 135.7M shares outstanding
52-week range
78.00p – 295.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£212,762 GBPMedian day 118,201 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Scancell Holdings PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:SCLP · Home79.00p GBX (pence)0.00 (0.0%)113,78380.00p82.00p78.00p79.00pClose on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:SCLP · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
79.00p0.000.0%80.00p82.00p78.00p113,783
79.00p-0.80-1.0%79.50p79.69p78.00p321,262
79.80p-4.20-5.0%81.00p81.00p79.20p165,584
84.00p+3.00+3.7%81.00p84.00p80.30p25,570
81.00p+1.00+1.3%80.00p82.00p79.00p111,348
80.00p0.000.0%79.50p81.00p79.05p163,968
80.00p0.000.0%80.00p81.00p79.00p1,130,672
80.00p-1.00-1.2%80.50p81.00p79.20p389,750
81.00p-3.00-3.6%83.00p83.00p80.00p409,378
84.00p+0.20+0.2%84.00p84.00p83.05p109,194
83.80p-1.20-1.4%85.50p85.99p83.80p259,372
85.00p-1.40-1.6%86.50p87.00p85.00p457,960
86.40p-1.60-1.8%88.00p88.00p86.00p58,269
88.00p+0.60+0.7%88.00p90.00p86.00p37,514
87.40p-1.60-1.8%89.00p90.00p86.50p77,114
89.00p0.000.0%89.00p90.00p88.00p106,170
89.00p0.000.0%89.00p90.00p88.31p98,494
89.00p-1.00-1.1%90.00p92.00p88.00p659,867
90.00p-1.00-1.1%91.00p92.00p88.00p134,631
91.00p0.000.0%91.00p92.00p90.00p86,331
91.00p+0.80+0.9%92.50p95.00p90.00p66,057
90.20p-2.80-3.0%89.50p95.00p89.50p87,877
93.00p0.000.0%93.50p94.00p92.40p15,087
93.00p0.000.0%93.50p94.00p93.00p8,254
93.00p-0.50-0.5%93.50p94.00p93.00p27,871
93.50p0.000.0%93.50p94.00p93.00p61,640
93.50p0.000.0%93.50p94.00p93.35p144,853
93.50p0.000.0%93.50p94.20p93.00p106,583
93.50p+0.50+0.5%93.50p94.00p93.00p89,627
93.00p-1.00-1.1%94.00p95.00p93.00p164,806
94.00p0.000.0%94.00p95.00p93.00p25,049
94.00p-0.50-0.5%94.50p95.00p93.00p130,603
94.50p+0.50+0.5%94.00p96.00p93.60p431,941
94.00p-1.00-1.1%94.00p95.00p93.00p82,443
95.00p+1.50+1.6%93.50p95.00p93.00p188,195
93.50p-0.50-0.5%94.00p94.00p93.00p135,035
94.00p-1.00-1.1%94.50p95.00p93.26p54,318
95.00p-0.50-0.5%95.50p96.00p94.00p111,623
95.50p0.000.0%95.50p96.00p95.00p84,920
95.50p-0.50-0.5%96.00p97.00p95.01p59,085
96.00p-1.00-1.0%98.00p99.00p95.25p199,138
97.00p0.000.0%98.00p99.00p97.00p115,318
97.00p-1.00-1.0%98.00p99.00p96.00p110,968
98.00p+0.50+0.5%97.50p99.00p96.80p129,088
97.50p-1.00-1.0%98.50p99.00p97.00p140,299
98.50p-0.50-0.5%98.50p99.20p98.00p88,829
99.00p+0.50+0.5%98.50p99.00p98.00p92,005
98.50p-1.00-1.0%99.50p102.00p98.00p103,500
99.50p-2.00-2.0%101.50p101.65p98.00p165,795
101.50p+0.50+0.5%100.50p102.00p100.00p1,029,377
101.00p+0.50+0.5%101.00p105.50p100.00p1,134,292
100.50p+1.50+1.5%99.00p105.00p98.00p724,681
99.00p+1.00+1.0%98.00p100.00p98.00p296,682
98.00p+2.40+2.5%96.00p99.00p95.90p256,517
95.60p+0.10+0.1%95.50p97.00p95.00p79,104
95.50p-0.50-0.5%96.00p97.00p95.35p236,125
96.00p0.000.0%96.00p97.00p95.00p163,009
96.00p-1.50-1.5%97.50p99.00p95.00p116,642
97.50p+1.30+1.4%96.00p99.00p95.65p118,201
96.20p-0.80-0.8%97.00p98.00p95.00p211,026
97.00p0.000.0%97.00p98.00p96.00p93,174
97.00p-1.00-1.0%98.00p98.20p96.30p212,988
98.00p+1.00+1.0%97.00p100.00p97.00p365,063
97.00p+2.00+2.1%95.50p98.00p95.00p938,933
95.00p-1.00-1.0%96.00p97.00p95.00p799,523

Splits

2 splits since 2011 · LSE:SCLP · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
10-for-1Split
Ticker
LSE:SCLP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Latest news

Result of AGM

Nov 19, 2026

Closed 79.00p (0.0%) on Nov 20, 2026

Notice of AGM

Oct 23, 2026

Closed 91.00p (0.0%) on Oct 23, 2026

Result of General Meeting

Oct 20, 2026

Closed 93.00p (0.0%) on Oct 20, 2026

Preliminary Results

Oct 9, 2026

Closed 93.00p (-1.1%) on Oct 9, 2026

Notice of GM

Oct 2, 2026

Closed 95.00p (+1.6%) on Oct 2, 2026

iSCIB1+ MHRA CTA Approval for Ph3 trial

Aug 19, 2026

Closed 96.00p (+1.1%) on Aug 19, 2026

All Scancell Holdings PLC news

Scancell Holdings PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 334 in all · newest Nov 19, 2026 · oldest 2008
Calls
1 call with a replay · 1 with a transcript · latest Jun 25, 2025
Decks
23 decks · latest August 2026

Where Scancell Holdings PLC is listed

ListingExchangeCountryCurrency
LSE:SCLP · Home listing · This pageLSEUnited KingdomGBX
OTC:SCNLFOTCUnited StatesUSD
AQUIS:SCLP.GBAQUISUnited KingdomGBX
Frankfurt:SCPFrankfurtGermanyEUR

Valuation

Statements: Year to Apr 30, 2026 · price Nov 20, 2026

Enterprise value
£118.9M GBP
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Scancell Holdings PLC · LSE:SCLPUS$140.2MUS$155.6Mn/an/an/an/an/an/an/a
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.0Mn/an/an/a3.7×n/a0.6×n/a
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.29Mn/a29.8×n/a1.4×n/a0.3×n/a
Protara Therapeutics, Inc. · NASDAQ:TARAUS$140.4MUS$15.77Mn/an/an/a1.0×n/a0.0×1.12
Cloudbreak Pharma, Inc. · HKEX:2592US$140.4MUS$82.03Mn/an/an/a2.3×n/a0.0×n/a
Abeona Therapeutics Inc. · NASDAQ:ABEOUS$138.4MUS$15.29Mn/a0.4×n/a1.1×−160.3%0.1×1.00
Median of the othersUS$143.8MUS$32.75M2.2×1.2×−190.2%0.1×1.14

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
300.00 GBX · Analysts' mean
EPS, year to Apr 2027
-0.020 · 1 analyst
Revenue, year to Apr 2027
1M · 2 analysts

Team and board

Officers

OfficerRole
David SchilanskyCFO
Mandeep SehmiInvestor Relations

Board

DirectorRole
Jean-Michel CosséryChair
Susan Clement DaviesDirector
Ursula NeyDirector

Events

Calls

CallWhenStatus
Scancell Holdings (LSE:SCLP) — Clinical and Corporate UpdateWed, Jun 25, 2025 · 6:00 AM ETReplay

Results days

QuarterResultsShare move
Q2 2026Jan 29, 2026−0.9%
Quarter to Jul 31, 2025Sep 11, 2025+7.1%
Q2 2025Jan 30, 2025−2.7%
Q2 2023Jan 25, 2023 · Before open−8.0%
Q1 2023Oct 28, 2022 · Before open+4.3%
Q2 2022Dec 22, 2021 · Before open−1.3%
Q1 2022Oct 29, 2021 · Before open−1.3%
Q2 2021Jan 29, 2021 · Before open−5.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck35 slidesAugust 2026
Investor Presentation (July 2026)Investor deck35 slidesJuly 2026
H1 FY2026 Earnings PresentationEarnings18 slidesJan 29, 2026
Technical Presentation (December 2025)Technical25 slidesDec 11, 2025
ESMO Immuno-Oncology Congress 2025Conference25 slidesDec 10, 2025
Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting 2025Conference16 slidesNovember 2025
H1 FY2025 Earnings PresentationEarnings27 slidesJanuary 2025
FY2024 Earnings PresentationEarnings20 slidesSep 24, 2024
Shareholder Meeting (November 2023)Shareholder meeting26 slidesNovember 2023
Shareholder Meeting (November 2021)Shareholder meeting41 slidesNovember 2021
All 23 decks
DeckKindSlidesDate
LSX World Congress 2020Conference21 slidesFebruary 2020
Shareholder Meeting (September 2019)Shareholder meeting18 slidesSep 12, 2019
Proactive One2One Investor Forum (April 2019)Conference27 slidesApr 25, 2019
LSX Inv€$tival Showcase 2018Conference20 slidesNov 13, 2018
China Healthcare Summit 2018Conference20 slidesNovember 2018
Proactive One2One Biotechnology Forum (November 2018)Conference27 slidesNovember 2018
Shareholder Meeting (October 2018)Shareholder meeting38 slidesOct 30, 2018
Investor Presentation (February 2018)Investor deck58 slidesFeb 16, 2018
Shareholder Meeting (October 2017)Shareholder meeting14 slidesOct 10, 2017
Shareholder Meeting (October 2016)Shareholder meeting17 slidesOct 18, 2016
Shareholder Meeting (October 2015)Shareholder meeting20 slidesOct 20, 2015
Shareholder Meeting (November 2012)Shareholder meeting8 slidesNov 6, 2012
Investor Presentation (March 2012)Investor deck22 slidesMar 13, 2012

Open Decks

Financings

RaiseDateIn US dollars
Private placement of private placement (PIPE Financing)
Update: US$39.1M · US$0.1205 a share · Leerink Partners +2
Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co.
Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs)
Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating
Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones
Oct 9, 2026
Loan facility, partly convertible into Ordinary Shares, with warrants
Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each…
Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility)
Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+
Oct 9, 2026
Private placement of new Ordinary Shares
Update: about US$12M · GBX 9 a share · Panmure Liberum Limited
Dealers: Panmure Liberum Limited (lead)
Jul 24, 2026
Ordinary Shares
Update: up to US$3M · GBX 9 a share
Jul 24, 2026
New ordinary shares (Retail Offer Shares)
Closed: £1M raised · GBX 10.5 a share · Winterflood Securities Limited
Dealers: Winterflood Securities Limited
Use of proceeds: Further working capital and balance sheet strength
Dec 9, 2024US$1.28M
Private placement of new ordinary shares (Placing Shares)
Made bigger: £10.3M · GBX 10.5 a share · Panmure Liberum Limited +1
Dealers: Panmure Liberum Limited (co-lead), WG Partners LLP (co-lead)
Buyers: Redmile Group, LLC (28,571,428 Placing Shares); Vulpes Investment Management (10,476,190 Placing Shares)
Insiders: Related parties Redmile and Vulpes, substantial shareholders, conditionally subscribing for 28,571,428 and 10,476,190 Placing Shares respectively
Use of proceeds: Progress lead cancer vaccine SCIB1 and next generation iSCIB1+, and extend cash runway to H2 2026
Dec 5, 2024US$13.13M
Private placement of new ordinary shares (Subscription Shares)
Update: about £20,000 · GBX 10.5 a share
Buyers: Sath Nirmalananthan (190,476 Ordinary Shares)
Insiders: Director and CFO Sath Nirmalananthan conditionally subscribed for 190,476 Ordinary Shares
Dec 5, 2024US$25,395

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue04.71M05.27M00000
Cost of revenue672.0K1.12M966.0K525.0K740.0K249.0K43.0K21.1K27.6K32.6K
Gross profit-672.0K3.59M-966.0K4.75M-740.0K-249.0K-43.0K-21.1K-27.6K-32.6K
Research and development12.0M14.7M12.9M11.6M9.48M6.41M4.67M4.15M2.85M2.77M
Selling, general and administrative5.39M4.79M5.40M5.02M4.79M3.35M2.12M2.58M2.09M1.78M
Operating income-17.4M-15.0M-18.3M-11.9M-14.3M-9.75M-6.78M-6.73M-4.94M-4.55M
Depreciation and amortization672.0K879.0K966.0K902.0K740.0K249.0K43.0K21.1K27.6K32.6K
EBITDA-16.8M-14.1M-17.3M-11.0M-13.5M-9.50M-6.74M-6.71M-4.91M-4.52M
Interest expense1.96M1.72M1.09M1.22M2.88M1.65M14.0K000
Income before tax-20.2M-15.3M-9.12M-14.3M-6.27M-16.8M-6.77M-6.71M-4.94M-4.50M
Income tax-2.33M-3.03M-3.26M-2.37M-1.70M-1.33M-1.26M-1.09M-745.0K-950.0K
Net income-17.9M-12.3M-5.86M-11.9M-2.06M-15.5M-5.51M-5.63M-4.20M-3.54M
Earnings per share, basic-0.17-0.13-0.07-0.15-0.03-0.23-0.12-0.14-0.13-0.13

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents5.32M16.9M14.8M19.9M41.1M41.1M4.56M4.56M10.3M2.67M
Receivables3.08M3.73M5.85M4.28M647.0K968.0K1.33M2.02M793.7K810.7K
Inventory533.0K-79.0K-1.93M-1.33M-793.7K-810.7K
Current assets8.40M20.6M21.9M24.6M32.4M44.7M7.07M7.07M11.1M3.52M
Property, plant and equipment2.74M975.0K195.0K58.0K76.9K93.1K
Goodwill3.42M3.42M3.42M3.42M3.42M3.42M3.42M
Total assets10.4M23.1M23.6M30.3M49.1M8.82M10.5M10.5M14.6M7.03M
Accounts payable821.0K606.0K1.46M1.31M2.14M821.0K395.0K716.0K356.3K274.7K
Current liabilities29.7M26.8M6.39M3.28M2.29M2.29M1.21M1.21M696.1K531.9K
Long-term debt017.4M18.5M7.01M15.2M0
Total debt17.1M16.3M19.9M21.1M18.9M15.4M129.0K
Total liabilities29.8M26.9M27.1M36.5M29.6M1.17M1.21M1.21M696.1K531.9K
Shareholders' equity-19.4M-3.83M-3.50M-6.23M18.1M19.5M9.34M9.34M13.9M6.50M
Shares outstanding103.8M97.0M86.2M81.6M81.6M67.9M46.6M39.5M31.9M26.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-10.6M-6.11M-15.7M-8.14M-7.80M-7.80M-7.03M-7.02M-4.06M-3.85M
Capital spending-94.0K-14.0K-177.0K-203.0K-744.0K-27.0K-2.66K-2.66K-11.4K-61.1K
Free cash flow-10.6M-6.12M-15.8M-8.34M-8.55M-4.80M-7.04M-7.02M-4.07M-3.91M
Cash from investing356.0K-1.54M178.0K81.0K-741.0K-13.0K12.3K-2.66K-8.66K-7.63K
Cash from financing-1.35M9.73M10.4M-746.0K46.1M46.1M1.28M1.28M11.7M11.7M
Share buybacks24.1M3.88M1.36M12.5M
Change in cash-11.6M2.08M-5.10M-8.80M37.5M-985.0K-5.74M-5.74M7.63M-3.86M

Open Financials

Filings

FilingDateTypeFiled with
F-4/ANov 18, 2026Offer documentSEC
F-4Oct 9, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Scancell Holdings PLC’s releases · as of Dec 9, 2024

Common shares
135,667,513
Fully diluted
135,667,513

Fully diluted

LineShares
Common shares135,667,513

Share count over time

CountShares
Nov 22, 2026135,667,513

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David SchilanskyCFO · Since at least Oct 15, 2026
Jean-Michel CosséryChair · Since at least Oct 15, 2026
Mandeep SehmiInvestor Relations · Since at least Jul 24, 2026
Susan Clement DaviesDirector · Since at least Jul 24, 2026
Ursula NeyDirector · Since at least Jul 24, 2026

Open People

Log in to ask 6ix AI your own questions about Scancell Holdings PLC.